--- title: "Pre-market hot trades in US stocks: AST SpaceMobile pre-market down 13.05%; Meiwu Tech pre-market down 12.87%" type: "News" locale: "en" url: "https://longbridge.com/en/news/283318326.md" description: "AST SpaceMobile pre-market down 13.05%; Meiwu Tech pre-market down 12.87%; Psyence Biomedical pre-market up 106.97%; Clearmind Medicine pre-market up 79.27%; Theriva Biologics pre-market up 58.67%" datetime: "2026-04-20T08:33:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283318326.md) - [en](https://longbridge.com/en/news/283318326.md) - [zh-HK](https://longbridge.com/zh-HK/news/283318326.md) --- # Pre-market hot trades in US stocks: AST SpaceMobile pre-market down 13.05%; Meiwu Tech pre-market down 12.87% **Pre-market Hot Trades in US Stocks** AST SpaceMobile is down 13.05% in pre-market trading. Based on recent key news: 1. On April 19, AST SpaceMobile's BlueBird 7 satellite launch failed to reach its intended orbit, leading to a drop in stock price. The satellite was sent to the wrong location and is expected to go out of orbit, with related losses covered by insurance. This incident has impacted the company's plans to accelerate the deployment of global 5G services. Source: Jinshi Data 2. On April 20, Blue Origin's rocket launch mission encountered a failure, failing to properly deploy AST SpaceMobile's satellite. This incident highlights the difficulty of launching complex equipment, affecting AST SpaceMobile's stock price. Source: You Analysis 3. On April 17, AST SpaceMobile announced the launch plan for the BlueBird 7 satellite, attracting market attention, but the subsequent launch failure put pressure on the stock price. Source: Reuters The competition in the low Earth orbit satellite market has intensified, increasing risks. Meiwu Tech is down 12.87% in pre-market trading. Based on recent key news: 1. On April 17, Meiwu Tech released its latest financial report, showing a significant decline in net profit for the first quarter, leading to a loss of investor confidence. According to the announcement released by Meiwu Tech in the EDGAR system of the U.S. Securities and Exchange Commission, net profit fell by more than 50% year-on-year, causing a sharp drop in stock price. 2. On April 16, industry competition intensified as major competitors launched new products, capturing market share. The market strategies and product innovations of competitors have put greater market pressure on Meiwu Tech, leading to further declines in stock price. 3. On April 15, macroeconomic data showed weakness, leading to overall market sentiment being low. The latest economic data indicated a slowdown in consumer spending and manufacturing activity, affecting the overall performance of tech stocks and dragging down Meiwu Tech's stock price. The competition in the tech industry has intensified, and macroeconomic data is weak. **Top Gainers in Pre-market US Stocks** Psyence Biomedical is up 106.97% in pre-market trading. Based on recent key news: 1. On April 17, Psyence Biomedical announced that its pharmaceutical-grade psilocybin product NPX-5 is being used in clinical trials, driving up the stock price. The company's CEO stated that this move will strengthen clinical infrastructure and support ongoing patient medication. The stock price rose 69.85% in pre-market trading, with significantly increased trading volume. Source: GlobeNewswire 2. On April 18, U.S. President Trump signed an executive order to expedite research and approval processes for psychedelic drugs, focusing on substances like ibogaine. This move aims to assist veterans suffering from mental illnesses and boost market expectations for related drugs. Source: Reuters On April 17, PsyLabs obtained federal licensing to support global distribution and clinical projects. The company implemented a 16-for-100 reverse stock split, with the stock price rising by 40.72%. Source: Nasdaq psychedelic drug research accelerates, market expectations rise. Clearmind Medicine pre-market rose by 79.27%. Based on recent key news: 1. On April 19, U.S. President Trump signed an executive order to accelerate research and approval processes for psychedelic therapies, focusing on drugs like ibogaine. This move aims to help veterans suffering from severe mental illnesses by providing new treatment options. The policy has driven up stock prices of related companies. 2. On April 18, Trump announced reforms to expedite access to medical research and treatments for psychedelic drugs. This will instruct the U.S. Food and Drug Administration to speed up reviews of drugs like ibogaine, which veteran groups believe can help treat post-traumatic stress disorder. This news further stimulated market interest in related companies. The psychedelic therapy policy has driven stock prices up. Theriva Biologics pre-market rose by 58.67%. Based on recent key news: 1. On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE 2B clinical trial at the AACR 2026 annual meeting, involving the application of VCN-01 in metastatic pancreatic cancer. This news has driven up the stock price. 2. On April 17, the company plans to conduct a small-scale dosing study to test whether more frequent and prolonged administration of VCN-01 can further improve outcomes. This move demonstrates the company's confidence in its product, further stimulating the stock price. 3. On April 17, Theriva Biologics released poster data from the VIRAGE 2B trial, showing that the combination of VCN-01 with GnP can improve overall and progression-free survival rates. This data has enhanced market confidence in the efficacy of VCN-01, driving up the stock price. The biotechnology sector has been active recently, with significant capital inflows ### Related Stocks - [ASTS.US](https://longbridge.com/en/quote/ASTS.US.md) - [WNW.US](https://longbridge.com/en/quote/WNW.US.md) ## Related News & Research - [Before the SpaceX IPO, buy these 3 cheap stocks](https://longbridge.com/en/news/287939824.md) - [This Is SpaceX's Biggest Market, and It Might Surprise You (Spoiler Alert: It Has Nothing to Do With Space)](https://longbridge.com/en/news/288140563.md) - [BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment](https://longbridge.com/en/news/287634369.md) - [11:04 ETVeeva anuncia Falcon, una plataforma para el desarrollo de fármacos](https://longbridge.com/en/news/287791359.md) - [08:00 ETCVS Health recognized for technology that improves medication safety and patient care](https://longbridge.com/en/news/288064061.md)